Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

Similar articles for PubMed (Select 22228633)

1.

Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.

Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, Riely GJ, Kris MG, Krug LM.

Clin Cancer Res. 2012 Feb 15;18(4):1138-45. doi: 10.1158/1078-0432.CCR-11-2059. Epub 2012 Jan 6.

2.

Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.

Inoue A, Sugawara S, Maemondo M, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T.

Lung Cancer. 2015 Jul;89(1):61-5. doi: 10.1016/j.lungcan.2015.04.012. Epub 2015 May 4.

PMID:
26004087
3.

Relevance of platinum sensitivity in patients with relapsed or refractory small-cell lung cancer.

Kim YH, Mishima M.

J Thorac Oncol. 2015 May;10(5):e35. doi: 10.1097/JTO.0000000000000513. No abstract available.

PMID:
25898966
4.

The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients.

Miura S, Kaira K, Kaira R, Akamatsu H, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Yamamoto N.

Invest New Drugs. 2015 Jun;33(3):755-60. doi: 10.1007/s10637-015-0233-7. Epub 2015 Apr 7.

PMID:
25846908
5.

Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).

Linardou H, Pentheroudakis G, Varthalitis I, Gogas H, Pectasides D, Makatsoris T, Fountzilas G, Bafaloukos D; Hellenic Cooperative Oncology Group.

Anticancer Res. 2015 Feb;35(2):1105-13.

PMID:
25667500
6.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.

Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

PMID:
25655102
7.

O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.

Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle JA, Molin Y, Lombard-Bohas C, Joly MO, Scoazec JY.

Br J Cancer. 2015 Feb 3;112(3):523-31. doi: 10.1038/bjc.2014.660. Epub 2015 Jan 13.

PMID:
25584486
8.

Role of MGMT as biomarker in colorectal cancer.

Inno A, Fanetti G, Di Bartolomeo M, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, de Braud F, Bossi I, Pietrantonio F.

World J Clin Cases. 2014 Dec 16;2(12):835-9. doi: 10.12998/wjcc.v2.i12.835. Review.

9.

MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.

Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C, Hertzman Johansson C, Lindén D, Johansson H, Frostvik Stolt M, Walker C, Snowden H, Newton-Bishop J, Hansson J, Egyházi Brage S.

Int J Cancer. 2015 Jun 15;136(12):2844-53. doi: 10.1002/ijc.29332. Epub 2014 Nov 24.

PMID:
25400033
10.

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Riely GJ, Kris MG, Krug LM, Pietanza MC.

Lung Cancer. 2014 Nov;86(2):237-40. doi: 10.1016/j.lungcan.2014.08.007. Epub 2014 Aug 17.

PMID:
25194640
11.

Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.

Brandwein JM, Kassis J, Leber B, Hogge D, Howson-Jan K, Minden MD, Galarneau A, Pouliot JF.

Br J Haematol. 2014 Dec;167(5):664-70. doi: 10.1111/bjh.13094. Epub 2014 Aug 27.

PMID:
25160658
12.

Predictive biomarkers investigated in glioblastoma.

Tabouret E, Chinot O, Sanson M, Loundou A, Hoang-Xuan K, Delattre JY, Idbaih A.

Expert Rev Mol Diagn. 2014 Sep;14(7):883-93. doi: 10.1586/14737159.2014.945436. Epub 2014 Aug 5. Review.

PMID:
25096963
13.

MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma.

Toffolatti L, Scquizzato E, Cavallin S, Canal F, Scarpa M, Stefani PM, Gherlinzoni F, Dei Tos AP.

Virchows Arch. 2014 Nov;465(5):579-86. doi: 10.1007/s00428-014-1622-6. Epub 2014 Jul 17.

PMID:
25031012
14.

Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.

Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L.

J Thorac Oncol. 2014 Apr;9(4):559-62. doi: 10.1097/JTO.0000000000000079.

15.

A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).

Murakami H, Yamamoto N, Shibata T, Takeda K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, Satouchi M, Kiura K, Nogami N, Endo M, Watanabe H, Tamura T.

Lung Cancer. 2014 Apr;84(1):67-72. doi: 10.1016/j.lungcan.2014.01.012. Epub 2014 Jan 25.

16.

O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer.

Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R.

J Carcinog. 2013 Oct 28;12:20. doi: 10.4103/1477-3163.120632. eCollection 2013.

17.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H.

Eur J Cancer. 2014 Jan;50(1):170-7. doi: 10.1016/j.ejca.2013.08.012. Epub 2013 Sep 7.

PMID:
24021349
18.

Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Matsuno A, Murakami M, Hoya K, Yamada SM, Miyamoto S, Yamada S, Son JH, Nishido H, Ide F, Nagashima H, Sugaya M, Hirohata T, Mizutani A, Okinaga H, Ishii Y, Tahara S, Teramoto A, Osamura RY.

Med Mol Morphol. 2014 Mar;47(1):1-7. doi: 10.1007/s00795-013-0050-z. Epub 2013 Aug 17. Review.

PMID:
23955641
19.

Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.

Lolli I, Morra I, Cimmino A, Trevisan E, Rudà R, Piombino M, Campanella G, Gillio Tos A, De Marco L, Trevisan M, Fiano V, Soffietti R.

J Clin Oncol. 2013 Aug 10;31(23):e394-7. doi: 10.1200/JCO.2012.47.5590. Epub 2013 Jun 24. No abstract available.

20.

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Jiang X, Reardon DA, Desjardins A, Vredenburgh JJ, Quinn JA, Austin AD, Herndon JE 2nd, McLendon RE, Friedman HS.

J Neurooncol. 2013 Aug;114(1):135-40. doi: 10.1007/s11060-013-1162-y. Epub 2013 May 18.

PMID:
23686298
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk